Bellicum Pharmaceuticals, Inc.
BLCM
BLCM was delisted on the 1st of June, 2023.
67 hedge funds and large institutions have $20.7M invested in Bellicum Pharmaceuticals, Inc. in 2019 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 15 increasing their positions, 26 reducing their positions, and 20 closing their positions.
812% more call options, than puts
Call options by funds: $301K | Put options by funds: $33K
15% less funds holding
Funds holding: 79 → 67 (-12)
42% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 26
51% less capital invested
Capital invested by funds: $42M → $20.7M (-$21.3M)
60% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.35M |
| 2 |
AC
Armistice Capital
New York
|
+$1.35M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$980K |
| 4 |
NAMA
Nikko Asset Management Americas
New York
|
+$328K |
| 5 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$328K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$4.06M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$1.18M |
| 3 |
Goldman Sachs
New York
|
-$862K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$424K |
| 5 |
Jane Street
New York
|
-$411K |
BLCM Hedge Fund Activity: Q3 2019 in Review
67 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q3 2019, worth a combined $20.7M — down 51% from $42M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of BLCM and 8 opened new positions — a net loss of 12 holders — while 26 trimmed existing stakes and 15 added.
The largest buyer was Renaissance Technologies, adding an estimated $1.35M. The largest seller was JP Morgan Chase, cutting an estimated $4.06M.
- 67 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q3 2019, down from 79 in Q2 2019.
- Funds reported $20.7M of Bellicum Pharmaceuticals, Inc. stock for Q3 2019, down 51% quarter-over-quarter.
- 8 funds opened new Bellicum Pharmaceuticals, Inc. positions in Q3 2019 and 20 closed out, a net change of -12 holders.
- The largest Bellicum Pharmaceuticals, Inc. buyer in Q3 2019 was Renaissance Technologies, an estimated $1.35M added.
- The largest Bellicum Pharmaceuticals, Inc. seller in Q3 2019 was JP Morgan Chase, an estimated $4.06M sold.
Based on aggregated 13F filings for Q3 2019.